EGFR and non-small cell lung carcinoma: With the iterative update of EGFR tyrosine kinase inhibitors (EGFR‐TKIs) and the treatment improvements, the 2‐year survival for NSCLC patients increased from 34% during 2009 through 2010 to 42% during 2015 through 2016 [4].